Farmitalia Carlo Erba

Carlo Erba

Maria M Usardi

Carmelo Gandolfi

Roberto Ceserani

Carlo Passarotti

Franco Faustini

Angelo Fumagalli

Alessandro Andreoni

Renato Pellegata

Gianfederico Doria

.omega.-Nor-cycloalkyl-13,14-dehydro-prostaglandin compounds, specifically 5c-9-oxo-11.alpha.,15S-dihydroxy-20,19,18-tirnor-17-cyclohexyl-prost-5-en- 13-ynoic acid, the esters and salts thereof, having antiulcer and luteolytic activity, are disclosed.

.omega.-Nor-cycloalkyl-13,14-dehydro-prostaglandins and process for

2-oxa-bicyclic prostaglandins are provided, together with methods for their preparation and pharmaceutical and veterinary compositions containing same. The compounds have a wide range of pharmacological utilities, such as hypotensive agents, vasodilatory agents, and anti-aggregating agents.

Certain PGI.sub.1 compounds and their pharmaceutical composition and

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities, including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Bicyclic prostaglandins and process for their preparation

Bicyclic prostaglandins and pharamaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities, including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Pharmaceutically useful 5,6-saturated PGI compounds

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds are also disclosed.

Bicyclic prostaglandins

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, antiaggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Bicyclic Prostaglandins and pharmaceutical and veterinary compositions containing them, having numerous pharmaceutical and veterinary utilities, including for example hypotensive, vasodilatory, anti-aggregating, and anti-thrombotic activities. Methods for preparing the compounds and compositions are also disclosed.

Bicyclic prostaglandins having numerous pharmaceutical and veterinary utilities including, for example, use as hypotensive, vasodilatory, anti-aggregating, cytoprotective, and bronchodilatory agents. Pharmaceutical and veterinary compositions comprising the compounds in combination with pharmaceutically and/or veterinarily acceptable carriers and/or diluents are also disclosed.

Certain 13,14-didehydro-PGI.sub.1 compounds

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them, having numerous pharmaceutical and veterinary utilities, including for example hypotensive, vasodilatory, anti-aggregating, and anti-thrombotic activities. Methods for preparing the compounds and compositions are also disclosed.

2-Oxa-bicyclic prostaglandins, a method for their preparation and pharmaceutical and veterinary compositions containing them are disclosed.

Certain PGI.sub.1 compounds and pharmaceutical compositions containing

Certain thiacyclic PGI compounds

New 2-oxa-bicyclic prostaglandin compounds, and pharmaceutical and veterinary compositions containing them, having pharmaceutical utility for example as anti-aggregating, vasodilating, and cytoprotective agents. Processes for preparing the compounds are also disclosed.

.omega.-NOR-CYCLOALKYL-13,14-DEHYDRO-PROSTAGLANDIN COMPOUNDS, SPECIFICALLY 13,14-DEHYDRO-17-CYCLOHEXYL-20,19,18-TRINOR-PGF.sub.2.alpha. having antiulcer and luteolytic activity, are disclosed.

.omega.-Nor-cycloalkyl-13,14-dehydro-prostaglandins

16S and 16R methyl 13, 14 dehydro PGE.sub.2 compounds have been prepared.

Growing community of inventors

Milan, Italy

Maria M Usardi